CV Sciences, Inc. (CVSI)
OTCMKTS · Delayed Price · Currency is USD
0.0381
-0.0019 (-4.75%)
Oct 27, 2025, 3:32 PM EDT
CV Sciences Revenue
CV Sciences had revenue of $3.62M in the quarter ending June 30, 2025, a decrease of -8.45%. This brings the company's revenue in the last twelve months to $14.98M, down -5.50% year-over-year. In the year 2024, CV Sciences had annual revenue of $15.71M, down -1.87%.
Revenue (ttm)
14.98M
Revenue Growth
-5.50%
P/S Ratio
0.46
Revenue / Employee
311.98K
Employees
49
Market Cap
6.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15.71M | -299.00K | -1.87% |
| Dec 31, 2023 | 16.00M | -201.00K | -1.24% |
| Dec 31, 2022 | 16.21M | -3.84M | -19.17% |
| Dec 31, 2021 | 20.05M | -4.38M | -17.93% |
| Dec 31, 2020 | 24.43M | -29.27M | -54.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
CV Sciences News
- 2 months ago - CV Sciences Launches Ignite: A Men's Performance Formula for Vitality, Recovery, Libido & ... - GuruFocus
- 2 months ago - CV Sciences Launches Ignite: A Men's Performance Formula for Vitality, Recovery, Libido & Focus - Accesswire
- 2 months ago - CV Sciences, Inc. (CVSI) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - CV Sciences Non-GAAP EPS of $0.00, revenue of $3.62M - Seeking Alpha
- 2 months ago - CV Sciences Sales Down 10 Percent - The Motley Fool
- 2 months ago - CV Sciences, Inc. Reports Second Quarter 2025 Financial Results - Accesswire
- 2 months ago - CV Sciences, Inc. To Announce Second Quarter 2025 Results On August 13, 2025 - Accesswire
- 4 months ago - Bullish Sentiment Across The Cannabis Space - Check Full Movers For June 24, 2025 - Benzinga